[go: up one dir, main page]

WO2008009868A3 - Procedes et outils pour la therapie de pathologies neurodegeneratives - Google Patents

Procedes et outils pour la therapie de pathologies neurodegeneratives Download PDF

Info

Publication number
WO2008009868A3
WO2008009868A3 PCT/FR2007/051706 FR2007051706W WO2008009868A3 WO 2008009868 A3 WO2008009868 A3 WO 2008009868A3 FR 2007051706 W FR2007051706 W FR 2007051706W WO 2008009868 A3 WO2008009868 A3 WO 2008009868A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
tools
neurodegenerative pathologies
strategy
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2007/051706
Other languages
English (en)
Other versions
WO2008009868A2 (fr
Inventor
Fabien Schweighoffer
Laurent Desire
Jerome Bourdin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ExonHit Therapeutics SA
Original Assignee
ExonHit Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ExonHit Therapeutics SA filed Critical ExonHit Therapeutics SA
Priority to EP07823624A priority Critical patent/EP2047277A2/fr
Priority to JP2009521315A priority patent/JP2009544964A/ja
Priority to AU2007274872A priority patent/AU2007274872A1/en
Priority to US12/309,492 priority patent/US20090317842A1/en
Priority to CA002658464A priority patent/CA2658464A1/fr
Publication of WO2008009868A2 publication Critical patent/WO2008009868A2/fr
Publication of WO2008009868A3 publication Critical patent/WO2008009868A3/fr
Priority to IL196643A priority patent/IL196643A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des compositions et méthodes pour le traitement de pathologies neurodégénératives dans lesquelles les fonctions cognitives sont altérées, comme observé dans la maladie d'Alzheimer. Plus particulièrement, l'invention présente une stratégie pour suivre en clinique humaine l'activité et/ou l'efficacité de traitements neuro-protecteurs, basée sur le dosage biochimique de certains paramètres des plaquettes, plus particulièrement la forme APP soluble alpha (sAPPalpha) de la protéine précurseur amyloïde, et donc réalisable à partir de prélèvements sanguins. L'invention concerne également des méthodes, outils, constructions et compositions adaptées à la mise en oeuvre de ces stratégies.
PCT/FR2007/051706 2006-07-21 2007-07-20 Procedes et outils pour la therapie de pathologies neurodegeneratives Ceased WO2008009868A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP07823624A EP2047277A2 (fr) 2006-07-21 2007-07-20 Procédés et outils pour la thérapie de pathologies neurodégénératives
JP2009521315A JP2009544964A (ja) 2006-07-21 2007-07-20 神経変性疾患の治療のための方法およびツール
AU2007274872A AU2007274872A1 (en) 2006-07-21 2007-07-20 Methods and tools for the therapy of neurodegenerative pathologies
US12/309,492 US20090317842A1 (en) 2006-07-21 2007-07-20 Methods and Tools for The Therapy of Neurodegenerative Pathologies
CA002658464A CA2658464A1 (fr) 2006-07-21 2007-07-20 Procedes et outils pour la therapie de pathologies neurodegeneratives
IL196643A IL196643A0 (en) 2006-07-21 2009-01-21 Methods and tools for the therapy of neurodegenerative pathologies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0606698A FR2904113A1 (fr) 2006-07-21 2006-07-21 Procedes et outils pour la therapie de pathologies neurodegeneratives
FR0606698 2006-07-21

Publications (2)

Publication Number Publication Date
WO2008009868A2 WO2008009868A2 (fr) 2008-01-24
WO2008009868A3 true WO2008009868A3 (fr) 2008-05-08

Family

ID=37736076

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/051706 Ceased WO2008009868A2 (fr) 2006-07-21 2007-07-20 Procedes et outils pour la therapie de pathologies neurodegeneratives

Country Status (11)

Country Link
US (1) US20090317842A1 (fr)
EP (1) EP2047277A2 (fr)
JP (1) JP2009544964A (fr)
KR (1) KR20090086386A (fr)
CN (1) CN101542289A (fr)
AU (1) AU2007274872A1 (fr)
CA (1) CA2658464A1 (fr)
FR (1) FR2904113A1 (fr)
IL (1) IL196643A0 (fr)
WO (1) WO2008009868A2 (fr)
ZA (1) ZA200901094B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110256559A1 (en) * 2008-10-20 2011-10-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method for Detecting Soluble Amyloid Precursor Protein (APP) Alpha and/or Soluble APP Beta
AU2017300579B2 (en) 2016-07-20 2023-02-09 Katholieke Universiteit Leuven, K.U.Leuven R&D Therapeutic agents for neurological and psychiatric disorders
JP6405549B2 (ja) * 2016-12-22 2018-10-17 国立研究開発法人理化学研究所 急性冠症候群のマーカー及びその利用
EP3628315A1 (fr) 2018-09-28 2020-04-01 Université de Caen Normandie Combinaison d'inhibiteur d'acétylcholinestérase et d'agoniste de récepteur de 5-ht4 comme agent neuroprotecteur dans le traitement de maladies neurodégénératives
EP3628660A1 (fr) 2018-09-28 2020-04-01 Université de Caen Normandie Donecopride et flucopride comme agents neuroprotectifs dans le traitement des maladies neurodégéneratives

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003038A1 (fr) * 1987-09-30 1989-04-06 Mathilde Elisabeth Boon Procede de diagnostic au moyen d'une ou de plusieurs cellules, et appareil a cet effet
US5843794A (en) * 1992-03-26 1998-12-01 Montefiore Medical Center Technique for the prevention of false positive reactions in immunological testing due to C1 and C1q components of the complement and method for screening for rheumatic factor
WO2001090084A1 (fr) * 2000-05-24 2001-11-29 Merck Sharp & Dohme Limited Derives de benzodiazepine utilises comme modulateurs de la proteine precurseur amyloide (app)
WO2003080609A1 (fr) * 2002-03-27 2003-10-02 Glaxo Group Limited Derives pyrazolopyrimidines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50103881D1 (de) * 2001-06-12 2004-11-04 Wiltfang Jens Monoklonaler Antikörper, mbAb 1E8, welcher für die zwei ersten N-terminalen Aminosäuren von Amyloid-beta-Peptiden spezifisch ist und dessen Verwendung zum Nachweis von Amyloid-beta Peptiden und/oder sAPPa

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003038A1 (fr) * 1987-09-30 1989-04-06 Mathilde Elisabeth Boon Procede de diagnostic au moyen d'une ou de plusieurs cellules, et appareil a cet effet
US5843794A (en) * 1992-03-26 1998-12-01 Montefiore Medical Center Technique for the prevention of false positive reactions in immunological testing due to C1 and C1q components of the complement and method for screening for rheumatic factor
WO2001090084A1 (fr) * 2000-05-24 2001-11-29 Merck Sharp & Dohme Limited Derives de benzodiazepine utilises comme modulateurs de la proteine precurseur amyloide (app)
WO2003080609A1 (fr) * 2002-03-27 2003-10-02 Glaxo Group Limited Derives pyrazolopyrimidines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BASKIN F ET AL: "Platelet APP isoform ratios correlate with declining cognition in AD.", NEUROLOGY 23 MAY 2000, vol. 54, no. 10, 23 May 2000 (2000-05-23), pages 1907 - 1909, XP002462506, ISSN: 0028-3878 *
TANG ET AL: "Platelet amyloid precursor protein processing: A bio-marker for Alzheimer's disease", JOURNAL OF NEUROLOGICAL SCIENCES, ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM, NL, vol. 240, no. 1-2, 15 January 2006 (2006-01-15), pages 53 - 58, XP005215581, ISSN: 0022-510X *

Also Published As

Publication number Publication date
FR2904113A1 (fr) 2008-01-25
EP2047277A2 (fr) 2009-04-15
CA2658464A1 (fr) 2008-01-24
JP2009544964A (ja) 2009-12-17
AU2007274872A1 (en) 2008-01-24
WO2008009868A2 (fr) 2008-01-24
KR20090086386A (ko) 2009-08-12
IL196643A0 (en) 2009-11-18
US20090317842A1 (en) 2009-12-24
ZA200901094B (en) 2010-01-27
CN101542289A (zh) 2009-09-23

Similar Documents

Publication Publication Date Title
WO2008006535A3 (fr) Utilisation d'une préparation colloïdale cationique pour le diagnostic et le traitement de maladies oculaires
WO2009149486A3 (fr) Composés destinés au traitement de maladies
WO2007038459A3 (fr) Composes de carboxyamine et leurs methodes d'utilisation
SI2104682T1 (sl) Diagnostika in zdravljenje Alzheimerjeve bolezni in drugih nevrodementnih bolezni
WO2006035237A3 (fr) Procedes et compositions lies a la maladie d'alzheimer
WO2006034373A3 (fr) Variants et variants chimiquement modifies de phenylalanine ammonia-lyase
WO2008076954A3 (fr) Composés hétérocycliques et procédés d'utilisation de ceux-ci
WO2010066684A3 (fr) Inhibiteurs pyridyloxyindoles de vegf-r2 et utilisation thérapeutique de ceux-ci
WO2007091250A8 (fr) Enzymotherapie de remplacement pour le traitement des maladies lysosomiales
WO2010057112A3 (fr) Variants génétiques intervenant dans la cognition humaine et leurs procédés d'utilisation comme cibles diagnostiques et thérapeutiques
WO2009093119A3 (fr) Utilisation d'inhibiteurs de sérine protéases pour traiter des maladies de peau
FR16C0029I2 (fr) Combinaisons medicamenteuses contenant de la benzoxazine pour traiter des maladies des voies respiratoires
WO2008096203A3 (fr) Extraits alimentaires destinés à un traitement contre les anomalies de lipoprotéines et contre les troubles et les maladies de peau
WO2006095029A3 (fr) Conjugues di-polymere-proteine et procedes de preparation de ceux-ci
WO2008009868A3 (fr) Procedes et outils pour la therapie de pathologies neurodegeneratives
WO2010064248A3 (fr) Procédés de diagnostic et de traitement des maladies des motoneurones
PT1778837E (pt) Tratamento de doenças neurodegenerativas por utilização de inibidores de scd4
WO2008152068A3 (fr) Dérivés de [1,10]-phénanthroline pour le traitement de maladies neurodégénératives ou hématologiques
WO2007056301A3 (fr) Thérapie avec un anticorps pour le traitement de maladies associées à l'intolérance au gluten
WO2008009655A3 (fr) Utilisation médicale de dérivés d'acides n-phénylpropénoyl-aminés et de composés apparentés
WO2007104768A3 (fr) Conjugués de protéines di-polymères et leurs procédés d'élaboration
WO2006053788A3 (fr) Modifications de keratoses seborrheiques et applications associees
WO2007081486A3 (fr) Administration orale de defensines pour traiter des maladies intestinales
WO2008011473A3 (fr) Compositions et leurs utilisations liées à l'hbxip
WO2005123651A8 (fr) L-2-(a-hydroxypentyle)benzoates, leur elaboration et leur utilisation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780034007.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07823624

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2658464

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009521315

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007823624

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007274872

Country of ref document: AU

Ref document number: 574859

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 978/CHENP/2009

Country of ref document: IN

Ref document number: 1020097003519

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: 2007274872

Country of ref document: AU

Date of ref document: 20070720

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12309492

Country of ref document: US